Ocular Therapeutix (OCUL) Gross Profit (2014 - 2026)

Ocular Therapeutix's Gross Profit history runs 13 years deep, the most recent figure standing at $9.5 million for Q1 2026.

• In Q1 2026, Gross Profit rose 374.09% year-over-year to $9.5 million; the TTM figure through Mar 2026 stood at $34.0 million (up 5.74% YoY), while the FY2025 annual figure was -$2.0 million, down 103.39% from the prior year.
• Gross Profit was $9.5 million for Q1 2026 at Ocular Therapeutix, up from $293000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $15.9 million in Q4 2024 to a low of -$21.9 million in Q4 2023.
• Historically, Gross Profit has averaged $6.5 million across 5 years, with a median of $9.5 million in 2026.
• The sharpest annual moves came in 2022 and 2023: Gross Profit jumped 654.3% in 2022, then plunged 267.29% in 2023.
• A 5-year view of Gross Profit shows it stood at $13.1 million in 2022, then slumped by 267.29% to -$21.9 million in 2023, then jumped by 172.54% to $15.9 million in 2024, then plunged by 98.15% to $293000.0 in 2025, then soared by 3127.3% to $9.5 million in 2026.
• The last three Gross Profit figures came in at $9.5 million (Q1 2026), $293000.0 (Q4 2025), and $12.8 million (Q3 2025), per Business Quant data.